Clinical trials: Lymphoid Neoplasms
Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Conditions
- Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia
- Trial name
- NCT00303966
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01273766
- Testing
- deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Lymphocytic, Lymphoblastic Lymphoma
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
AINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and lymphoblastic lymphoma (LL).
- Conditions
- Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia
- Trial name
- NCT03792256
- Testing
- Palbociclib, Cytarabine, Methotrexate
- Where
- 19 sites in United States
- Volunteers
- 12 people
- Sponsor
- Children's Oncology Group
T-LGL Lymphoproliferative Disorders
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
This study will examine the use of alemtuzumab (Campath) in patients with T cell large granular lymphocytic leukemia (T-LGL). Patients with T-LGL often have reduced white blood cells, red blood cells and platelets, and increased…
- Trial name
- NCT00345345
- Testing
- Alemtuzumab (Campath)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00398112
- Testing
- sunitinib malate, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
A Study of Actonel for the Prevention of Bone Loss
The goal of this clinical research study is to learn if Actonel (risedronate) can help to prevent the development of osteoporosis (brittle and weak bones) caused by the steroid medication used to treat leukemia.
- Trial name
- NCT00452439
- Testing
- Actonel (Risedronate), Calcium, Vitamin D
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
This phase II clinical trial studies how well soy isoflavones work in preventing head and neck cancer in patients with stage I-IV head and neck cancer undergoing surgery.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT02007200
- Testing
- Laboratory Biomarker Analysis, Soy Isoflavones, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML)
Unrelated Umbilical Cord Blood (UBC)Transplantation
Hematopoietic progenitor cell (HPC- primitive cells in the blood, bone marrow and umbilical cord that can restore the bone marrow) transplant can be a curative therapy for the treatment of hematologic malignancies (a disease of…
- Conditions
- Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT01768845
- Testing
- umbilical cord blood (UCB)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- West Virginia University
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Trial name
- NCT04029688
- Testing
- Idasanutlin, Venetoclax, Cyclophosphamide
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source.
- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
- Trial name
- NCT02581007
- Testing
- Fludarabine, Melphalan, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northside Hospital, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
This study evaluates ADCT-301 in participants with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). Participants will participate in a dose-escalation phase (Part 1) and receive ADCT-301 either weekly or once…
- Trial name
- NCT02588092
- Testing
- ADCT-301
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- ADC Therapeutics S.A.
Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r…
- Trial name
- ZUMA-8 (NCT03624036)
- Testing
- brexucabtagene autoleucel, Fludarabine, Cyclophosphamide
- Where
- 22 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Kite, A Gilead Company
Acute Lymphoblastic Leukemia
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
This is an open-label, single-arm, multicenter study in Chinese patients with relapsed or refractory CD22-positive B-cell ALL. The objective of the study is to confirm the efficacy, safety, and PK of inotuzumab ozogamicin in…
- Trial name
- NCT05687032
- Testing
- inotuzumab ozogamicin
- Where
- 16 sites in China
- Volunteers
- 44 people
- Sponsor
- Pfizer
Advanced B-cell Lymphoid Malignancies
Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)
This is a Phase 0/1 open-label, non-randomized, biomarker and pharmacodynamic study in patients with advanced B-cell lymphoid malignancies, including B-cell chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL)…
- Trial name
- NCT01888952
- Testing
- Prednisone, Roflumilast
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Anand B. Karnad
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
The main purpose of this study is to see if ofatumumab with methylprednisolone followed by additional treatment with ofatumumab and lenalidomide can help people with Chronic Lymphocytic Leukemia (CLL) get rid of their CLL for a…
- Trial name
- NCT01496976
- Testing
- High Dose Methylprednisolone (HDMP), Ofatumumab, Lenalidomide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can kill chronic lymphocytic leukemia (CLL) cells and are effective therapies for this disease.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
- Trial name
- NCT01269385
- Testing
- alemtuzumab, rituximab, PGG beta-glucan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Follicular Lymphoma (FL), CLL
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
- Conditions
- Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome
- Trial name
- KEYNOTE145 (NCT02362035)
- Testing
- Acalabrutinib, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 161 people
- Sponsor
- Acerta Pharma BV
Chronic Myeloproliferative Disorders, Leukemia
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00691015
- Testing
- rituximab, busulfan, carmustine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lymphocytic Leukemia, Chronic
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
This randomized, open-label, parallel group study will assess the effect on response rate and the safety of MabThera added to either bendamustine or chlorambucil in patients with chronic lymphocytic leukemia.
- Trial name
- NCT01056510
- Testing
- bendamustine, chlorambucil, rituximab [MabThera/Rituxan]
- Where
- 85 sites in Finland, France and 6 more
- Volunteers
- 357 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.